Korrektur
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
New England Journal of Medicine · 26.03.2026 · 394 (12) · 1248-1248
DOI: 10.1056/nejmx250014 ↗Kurz gefasst
Korrektur in der Zeitschrift New England Journal of Medicine, erschienen am 26.03.2026. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine, 394(12), 1248-1248. https://doi.org/10.1056/nejmx250014
Vancouver
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis. New England Journal of Medicine. 2026;394(12):1248-1248. doi:10.1056/nejmx250014
BibTeX
@article{euvimed2026,
title = {Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {12},
pages = {1248--1248},
doi = {10.1056/nejmx250014}
}
EUVIMED